ent-01
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 15, 2017 (NCT03047629)
Timeline
Indications
Mechanism of action
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ent-01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04483479 | Phase 2 | Jul 30, 2020 | Enterin Inc. |
| NCT03938922 | Phase 1 | Jun 13, 2019 | Enterin Inc. |
| NCT03781791 | Phase 2 | Dec 10, 2018 | Enterin Inc. |
| NCT03047629 | Phase 1/Phase 2 (Phase 2) | May 15, 2017 | Enterin Inc., Georgetown University, University of Toronto |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enterin Inc. | For profit | 4 | 4 | 2 | 2017 |
| Georgetown University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1